# Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

> **NCT01940965** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 294 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** lixisenatide AVE0010
- **DRUG:** biguanide
- **DRUG:** TZD
- **DRUG:** alpha-GI
- **DRUG:** glinide

## Key facts

- **NCT ID:** NCT01940965
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 294 (ACTUAL)
- **Last updated:** 2015-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01940965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01940965, "Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01940965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*